Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases
Posaconazole (POS) is an extended-spectrum triazole approved for treatment of refractory invasive fungal disease. Outcome analysis of POS salvage therapy is of great clinical significance. We retrospectively reviewed data for 113 patients who received POS oral suspension as salvage therapy between D...
Gespeichert in:
| Veröffentlicht in: | Future microbiology 2019-04, Vol.14 (6), p.477-488 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 488 |
|---|---|
| container_issue | 6 |
| container_start_page | 477 |
| container_title | Future microbiology |
| container_volume | 14 |
| creator | Zhang, Sudong Zhang, Ping Wang, Zhao Liu, Li He, Yi Jiang, Erlie Wei, Jialin Yang, Donglin Zhang, Rongli Zhai, Weihua Ma, Qiaoling Pang, Aiming Huang, Yong Han, Mingzhe Feng, Sizhou |
| description | Posaconazole (POS) is an extended-spectrum triazole approved for treatment of refractory invasive fungal disease. Outcome analysis of POS salvage therapy is of great clinical significance.
We retrospectively reviewed data for 113 patients who received POS oral suspension as salvage therapy between December 2013 and May 2018.
Cumulative success rate at 12 weeks was 53.1% (60/113) with a rapid increase within the first 3-4 weeks and a plateau at 6 weeks after POS initiation. Multivariate logistic regression analysis showed that disseminated infection, prolonged neutropenia, severe graft-versus-host disease and high-dose steroid use were independent risk factors of response.
POS oral suspension is effective as a salvage therapy for invasive fungal disease. |
| doi_str_mv | 10.2217/fmb-2018-0344 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2193166725</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2276838138</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-ad5a5dc41cbf0a726d726d5ec63122c586e1fde1d5feb2b1d187aab39cd169613</originalsourceid><addsrcrecordid>eNp1kcuLFDEQxoMo7kOPXiXgxUtrKunnUZb1AQt60HOoTqpnsnR32lT3LOtfb4ZZVxA8FPXgVx9FfUK8AvVOa2jeD1NfaAVtoUxZPhHn0JR1oToNTx9rMGfigvlWqaqFDp6LM6Papiwrcy74W2R0ccZfcSQZE46SN15o5hBniSwZxwPuSK57SrjcyyEmGeYDcjiQHLZ5lzd8YEKmPJcLroHmleVdWPdyTxOucYy74P5i_EI8G3BkevmQL8WPj9ffrz4XN18_fbn6cFM408BaoK-w8q4E1w8KG137Y1TkagNau6qtCQZP4KuBet2Dh7ZB7E3nPNRdDeZSvD3pLin-3IhXOwV2NI44U9zYaugM1HWjq4y--Qe9jVua83VW66ZuTQumzVRxolyKzIkGu6QwYbq3oOzRDZvdsEc37NGNzL9-UN36ifwj_ef9GehOwLCtWyJ2-XeO7KnLG8GFmf4j_hv74Jt-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2276838138</pqid></control><display><type>article</type><title>Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases</title><source>MEDLINE</source><source>PubMed Central</source><creator>Zhang, Sudong ; Zhang, Ping ; Wang, Zhao ; Liu, Li ; He, Yi ; Jiang, Erlie ; Wei, Jialin ; Yang, Donglin ; Zhang, Rongli ; Zhai, Weihua ; Ma, Qiaoling ; Pang, Aiming ; Huang, Yong ; Han, Mingzhe ; Feng, Sizhou</creator><creatorcontrib>Zhang, Sudong ; Zhang, Ping ; Wang, Zhao ; Liu, Li ; He, Yi ; Jiang, Erlie ; Wei, Jialin ; Yang, Donglin ; Zhang, Rongli ; Zhai, Weihua ; Ma, Qiaoling ; Pang, Aiming ; Huang, Yong ; Han, Mingzhe ; Feng, Sizhou</creatorcontrib><description>Posaconazole (POS) is an extended-spectrum triazole approved for treatment of refractory invasive fungal disease. Outcome analysis of POS salvage therapy is of great clinical significance.
We retrospectively reviewed data for 113 patients who received POS oral suspension as salvage therapy between December 2013 and May 2018.
Cumulative success rate at 12 weeks was 53.1% (60/113) with a rapid increase within the first 3-4 weeks and a plateau at 6 weeks after POS initiation. Multivariate logistic regression analysis showed that disseminated infection, prolonged neutropenia, severe graft-versus-host disease and high-dose steroid use were independent risk factors of response.
POS oral suspension is effective as a salvage therapy for invasive fungal disease.</description><identifier>ISSN: 1746-0913</identifier><identifier>EISSN: 1746-0921</identifier><identifier>DOI: 10.2217/fmb-2018-0344</identifier><identifier>PMID: 30874453</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Adolescent ; Adult ; allogeneic hematopoietic stem cell transplantation ; Antifungal agents ; Antifungal Agents - therapeutic use ; Cancer therapies ; Cytomegalovirus ; Disease ; Disseminated infection ; Drug dosages ; FDA approval ; Female ; Fungal diseases ; Fungal infections ; Graft vs Host Disease - etiology ; Graft-versus-host reaction ; Hematologic Diseases - complications ; Hematological diseases ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; invasive fungal disease ; Invasive Fungal Infections - complications ; Invasive Fungal Infections - drug therapy ; Logistic Models ; Male ; Medical treatment ; Middle Aged ; Neutropenia ; Neutropenia - etiology ; Patients ; Posaconazole ; Regression analysis ; Retrospective Studies ; Risk factors ; Salvage Therapy ; Stem cell transplantation ; Stem cells ; Transplantation, Homologous ; Transplants & implants ; Treatment Outcome ; Triazoles - adverse effects ; Triazoles - therapeutic use ; Young Adult</subject><ispartof>Future microbiology, 2019-04, Vol.14 (6), p.477-488</ispartof><rights>2019 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Apr 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-ad5a5dc41cbf0a726d726d5ec63122c586e1fde1d5feb2b1d187aab39cd169613</citedby><cites>FETCH-LOGICAL-c371t-ad5a5dc41cbf0a726d726d5ec63122c586e1fde1d5feb2b1d187aab39cd169613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30874453$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Sudong</creatorcontrib><creatorcontrib>Zhang, Ping</creatorcontrib><creatorcontrib>Wang, Zhao</creatorcontrib><creatorcontrib>Liu, Li</creatorcontrib><creatorcontrib>He, Yi</creatorcontrib><creatorcontrib>Jiang, Erlie</creatorcontrib><creatorcontrib>Wei, Jialin</creatorcontrib><creatorcontrib>Yang, Donglin</creatorcontrib><creatorcontrib>Zhang, Rongli</creatorcontrib><creatorcontrib>Zhai, Weihua</creatorcontrib><creatorcontrib>Ma, Qiaoling</creatorcontrib><creatorcontrib>Pang, Aiming</creatorcontrib><creatorcontrib>Huang, Yong</creatorcontrib><creatorcontrib>Han, Mingzhe</creatorcontrib><creatorcontrib>Feng, Sizhou</creatorcontrib><title>Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases</title><title>Future microbiology</title><addtitle>Future Microbiol</addtitle><description>Posaconazole (POS) is an extended-spectrum triazole approved for treatment of refractory invasive fungal disease. Outcome analysis of POS salvage therapy is of great clinical significance.
We retrospectively reviewed data for 113 patients who received POS oral suspension as salvage therapy between December 2013 and May 2018.
Cumulative success rate at 12 weeks was 53.1% (60/113) with a rapid increase within the first 3-4 weeks and a plateau at 6 weeks after POS initiation. Multivariate logistic regression analysis showed that disseminated infection, prolonged neutropenia, severe graft-versus-host disease and high-dose steroid use were independent risk factors of response.
POS oral suspension is effective as a salvage therapy for invasive fungal disease.</description><subject>Adolescent</subject><subject>Adult</subject><subject>allogeneic hematopoietic stem cell transplantation</subject><subject>Antifungal agents</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Cytomegalovirus</subject><subject>Disease</subject><subject>Disseminated infection</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Female</subject><subject>Fungal diseases</subject><subject>Fungal infections</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft-versus-host reaction</subject><subject>Hematologic Diseases - complications</subject><subject>Hematological diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>invasive fungal disease</subject><subject>Invasive Fungal Infections - complications</subject><subject>Invasive Fungal Infections - drug therapy</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Neutropenia</subject><subject>Neutropenia - etiology</subject><subject>Patients</subject><subject>Posaconazole</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Salvage Therapy</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplantation, Homologous</subject><subject>Transplants & implants</subject><subject>Treatment Outcome</subject><subject>Triazoles - adverse effects</subject><subject>Triazoles - therapeutic use</subject><subject>Young Adult</subject><issn>1746-0913</issn><issn>1746-0921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kcuLFDEQxoMo7kOPXiXgxUtrKunnUZb1AQt60HOoTqpnsnR32lT3LOtfb4ZZVxA8FPXgVx9FfUK8AvVOa2jeD1NfaAVtoUxZPhHn0JR1oToNTx9rMGfigvlWqaqFDp6LM6Papiwrcy74W2R0ccZfcSQZE46SN15o5hBniSwZxwPuSK57SrjcyyEmGeYDcjiQHLZ5lzd8YEKmPJcLroHmleVdWPdyTxOucYy74P5i_EI8G3BkevmQL8WPj9ffrz4XN18_fbn6cFM408BaoK-w8q4E1w8KG137Y1TkagNau6qtCQZP4KuBet2Dh7ZB7E3nPNRdDeZSvD3pLin-3IhXOwV2NI44U9zYaugM1HWjq4y--Qe9jVua83VW66ZuTQumzVRxolyKzIkGu6QwYbq3oOzRDZvdsEc37NGNzL9-UN36ifwj_ef9GehOwLCtWyJ2-XeO7KnLG8GFmf4j_hv74Jt-</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Zhang, Sudong</creator><creator>Zhang, Ping</creator><creator>Wang, Zhao</creator><creator>Liu, Li</creator><creator>He, Yi</creator><creator>Jiang, Erlie</creator><creator>Wei, Jialin</creator><creator>Yang, Donglin</creator><creator>Zhang, Rongli</creator><creator>Zhai, Weihua</creator><creator>Ma, Qiaoling</creator><creator>Pang, Aiming</creator><creator>Huang, Yong</creator><creator>Han, Mingzhe</creator><creator>Feng, Sizhou</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190401</creationdate><title>Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases</title><author>Zhang, Sudong ; Zhang, Ping ; Wang, Zhao ; Liu, Li ; He, Yi ; Jiang, Erlie ; Wei, Jialin ; Yang, Donglin ; Zhang, Rongli ; Zhai, Weihua ; Ma, Qiaoling ; Pang, Aiming ; Huang, Yong ; Han, Mingzhe ; Feng, Sizhou</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-ad5a5dc41cbf0a726d726d5ec63122c586e1fde1d5feb2b1d187aab39cd169613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>allogeneic hematopoietic stem cell transplantation</topic><topic>Antifungal agents</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Cytomegalovirus</topic><topic>Disease</topic><topic>Disseminated infection</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Female</topic><topic>Fungal diseases</topic><topic>Fungal infections</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft-versus-host reaction</topic><topic>Hematologic Diseases - complications</topic><topic>Hematological diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>invasive fungal disease</topic><topic>Invasive Fungal Infections - complications</topic><topic>Invasive Fungal Infections - drug therapy</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Neutropenia</topic><topic>Neutropenia - etiology</topic><topic>Patients</topic><topic>Posaconazole</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Salvage Therapy</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplantation, Homologous</topic><topic>Transplants & implants</topic><topic>Treatment Outcome</topic><topic>Triazoles - adverse effects</topic><topic>Triazoles - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Sudong</creatorcontrib><creatorcontrib>Zhang, Ping</creatorcontrib><creatorcontrib>Wang, Zhao</creatorcontrib><creatorcontrib>Liu, Li</creatorcontrib><creatorcontrib>He, Yi</creatorcontrib><creatorcontrib>Jiang, Erlie</creatorcontrib><creatorcontrib>Wei, Jialin</creatorcontrib><creatorcontrib>Yang, Donglin</creatorcontrib><creatorcontrib>Zhang, Rongli</creatorcontrib><creatorcontrib>Zhai, Weihua</creatorcontrib><creatorcontrib>Ma, Qiaoling</creatorcontrib><creatorcontrib>Pang, Aiming</creatorcontrib><creatorcontrib>Huang, Yong</creatorcontrib><creatorcontrib>Han, Mingzhe</creatorcontrib><creatorcontrib>Feng, Sizhou</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Sudong</au><au>Zhang, Ping</au><au>Wang, Zhao</au><au>Liu, Li</au><au>He, Yi</au><au>Jiang, Erlie</au><au>Wei, Jialin</au><au>Yang, Donglin</au><au>Zhang, Rongli</au><au>Zhai, Weihua</au><au>Ma, Qiaoling</au><au>Pang, Aiming</au><au>Huang, Yong</au><au>Han, Mingzhe</au><au>Feng, Sizhou</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases</atitle><jtitle>Future microbiology</jtitle><addtitle>Future Microbiol</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>14</volume><issue>6</issue><spage>477</spage><epage>488</epage><pages>477-488</pages><issn>1746-0913</issn><eissn>1746-0921</eissn><abstract>Posaconazole (POS) is an extended-spectrum triazole approved for treatment of refractory invasive fungal disease. Outcome analysis of POS salvage therapy is of great clinical significance.
We retrospectively reviewed data for 113 patients who received POS oral suspension as salvage therapy between December 2013 and May 2018.
Cumulative success rate at 12 weeks was 53.1% (60/113) with a rapid increase within the first 3-4 weeks and a plateau at 6 weeks after POS initiation. Multivariate logistic regression analysis showed that disseminated infection, prolonged neutropenia, severe graft-versus-host disease and high-dose steroid use were independent risk factors of response.
POS oral suspension is effective as a salvage therapy for invasive fungal disease.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>30874453</pmid><doi>10.2217/fmb-2018-0344</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-0913 |
| ispartof | Future microbiology, 2019-04, Vol.14 (6), p.477-488 |
| issn | 1746-0913 1746-0921 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2193166725 |
| source | MEDLINE; PubMed Central |
| subjects | Adolescent Adult allogeneic hematopoietic stem cell transplantation Antifungal agents Antifungal Agents - therapeutic use Cancer therapies Cytomegalovirus Disease Disseminated infection Drug dosages FDA approval Female Fungal diseases Fungal infections Graft vs Host Disease - etiology Graft-versus-host reaction Hematologic Diseases - complications Hematological diseases Hematology Hematopoietic Stem Cell Transplantation Humans invasive fungal disease Invasive Fungal Infections - complications Invasive Fungal Infections - drug therapy Logistic Models Male Medical treatment Middle Aged Neutropenia Neutropenia - etiology Patients Posaconazole Regression analysis Retrospective Studies Risk factors Salvage Therapy Stem cell transplantation Stem cells Transplantation, Homologous Transplants & implants Treatment Outcome Triazoles - adverse effects Triazoles - therapeutic use Young Adult |
| title | Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T13%3A21%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Posaconazole%20oral%20suspension%20as%20salvage%20therapy%20for%20invasive%20fungal%20disease%20in%20patients%20with%20hematological%20diseases&rft.jtitle=Future%20microbiology&rft.au=Zhang,%20Sudong&rft.date=2019-04-01&rft.volume=14&rft.issue=6&rft.spage=477&rft.epage=488&rft.pages=477-488&rft.issn=1746-0913&rft.eissn=1746-0921&rft_id=info:doi/10.2217/fmb-2018-0344&rft_dat=%3Cproquest_cross%3E2276838138%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2276838138&rft_id=info:pmid/30874453&rfr_iscdi=true |